Acorda questions real parties-in-interest in first Bass IPR
Acorda has filed a preliminary response to Kyle Bass’s first IPR petition, claiming the petition should be rejected for reasons including the petitioner using IPR as a tool to manipulate markets and failing to mention its investors and identifying them as real parties-in-interest
Biotechnology company Acorda has filed its preliminary response to an inter partes review (IPR) petition challenging its Patent Number 8,663,685 at the Patent Trial and Appeal Board (PTAB). The petition was brought by the Coalition for Affordable Drugs, backed by...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.